{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:00:45Z","timestamp":1784768445721,"version":"3.55.0"},"reference-count":40,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis Care &amp;amp; Research"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study assessed sarilumab in treating patients with polyarticular\u2010course juvenile idiopathic arthritis (pcJIA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This phase 2b, open\u2010label study (NCT02776735) consisted of three sequential parts (each with a core\u2010treatment and extension phase). During part 1, three doses were assessed in two weight groups (group A\/B: \u226530\u201360 kg\/\u226510 to &lt;30 kg) to select the optimal dose with regard to pharmacokinetics, safety and efficacy were evaluated in latter parts. During the extension phase of part 1, patients initially assigned to the selected optimal dose continued on this dose; the remaining patients were switched to this selected dose. Patients in parts 2 and 3 received the selected dose from baseline. The primary endpoint was pharmacokinetic exposure (area under the serum concentration versus time curve during a dose interval \u0547 of 2 weeks [AUC\n                      <jats:sub>0\u2013\u0547<\/jats:sub>\n                      ], maximum serum concentration observed [C\n                      <jats:sub>max<\/jats:sub>\n                      ], and concentrations observed before treatment administration during repeated dosing [C\n                      <jats:sub>trough<\/jats:sub>\n                      ]). Safety and efficacy were assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean age of treated patients (N = 101; 76.2% female) was 9.4 years. Of the evaluated doses in part 1, dose 2 (group A\/B: 3.0\/4.0 mg\/kg every 2 weeks [q2w]) was selected. In patients receiving the selected dose from baseline (n = 73), C\n                      <jats:sub>max<\/jats:sub>\n                      , AUC\n                      <jats:sub>0\u201314 days<\/jats:sub>\n                      and C\n                      <jats:sub>trough<\/jats:sub>\n                      at steady state in group A\/B were 27.1\/40.4 mg\/L, 276\/395\u2010day*mg\/L, and 9.57\/14.4 mg\/L, respectively. At week 48, the JIA\u2013American College of Rheumatology 30%, 50%, 70%, and 90% improvement criteria rates were 100%, 100%, 93.8%, and 76.6%, respectively. Adverse events were reported in 70 of 73 patients (95.9%). Twenty\u2010seven patients (37%) experienced grade 3\/4 neutropenia; there were no associated infections. No deaths occurred.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with pcJIA receiving the selected dose from baseline, pharmacokinetic exposure was comparable to a dose of 200 mg q2w for adults with rheumatoid arthritis. Clinically relevant improvements were observed in disease activity, with safety being consistent with the known profile of sarilumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr.25692","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T13:57:57Z","timestamp":1763128677000},"page":"749-760","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sarilumab in Polyarticular\u2010Course Juvenile Idiopathic Arthritis: Dose\u2010Finding and 1\u2010Year Analysis of a Phase 2b, Open\u2010Label, Multicenter Study"],"prefix":"10.1002","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8749-8232","authenticated-orcid":false,"given":"Fabrizio","family":"De Benedetti","sequence":"first","affiliation":[{"name":"Ospedale Pediatrico Bambino Ges\u00f9 IRCCS, ERN\u2010RITA Center  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada C.","family":"Penad\u00e9s","sequence":"additional","affiliation":[{"name":"Hospital Universitario y Polit\u00e9cnico la Fe  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Nikishina","sequence":"additional","affiliation":[{"name":"V. A. Nasonova Research Institute of Rheumatology  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0659-5298","authenticated-orcid":false,"given":"Ivan","family":"Foeldvari","sequence":"additional","affiliation":[{"name":"Am Schoen Klinik Eilbek  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto J.","family":"Spindler","sequence":"additional","affiliation":[{"name":"Centro M\u00e9dico Privado de Reumatologia  Tucum\u00e1n Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kozlova","sequence":"additional","affiliation":[{"name":"Centre of Pediatric Hematology, Oncology and Immunology  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadina","family":"Rubio\u2010P\u00e9rez","sequence":"additional","affiliation":[{"name":"Hospital Universitario \u201cDr. J. E. Gonz\u00e1lez,\u201d Universidad Aut\u00f3noma de Nuevo Le\u00f3n  Monterrey Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Quartier","sequence":"additional","affiliation":[{"name":"Necker\u2010Enfants Malades Hospital, Assistance Publique\u2010Hopitaux de Paris  Paris France"},{"name":"Universit\u00e9 Paris\u2010Cit\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbigniew","family":"\u017buber","sequence":"additional","affiliation":[{"name":"Andrzej Frycz Modrzewski Krakow University  Krakow Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Barria","sequence":"additional","affiliation":[{"name":"Bioreuma  Concepci\u00f3n Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Clemente","sequence":"additional","affiliation":[{"name":"Hospital Infantil Universitario Ni\u00f1o Jes\u00fas  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel V.","family":"Cornejo","sequence":"additional","affiliation":[{"name":"Clinica de Reumatologia y Enfermedades Autoinmunes  Guadalajara Jalisco Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Marzan","sequence":"additional","affiliation":[{"name":"Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California  Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Liu","sequence":"additional","affiliation":[{"name":"Sanofi  Morristown New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Xu","sequence":"additional","affiliation":[{"name":"Sanofi  Morristown New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9165-9419","authenticated-orcid":false,"given":"Stephen","family":"DiMartino","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc  Tarrytown New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeliki","family":"Giannelou","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc  Tarrytown New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Cao\u2010Ghoul","sequence":"additional","affiliation":[{"name":"Sanofi  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolanle","family":"Akinlade","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc  Tarrytown New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydie","family":"Baret\u2010Cormel","sequence":"additional","affiliation":[{"name":"Sanofi  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"issue":"2","key":"e_1_2_8_2_1","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty RE","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2013.09.003"},{"key":"e_1_2_8_4_1","first-page":"379","article-title":"Polyarticular juvenile idiopathic arthritis \u2010 epidemiology and management approaches","volume":"6","author":"Oberle EJ","year":"2014","journal-title":"Clin Epidemiol"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-020-00443-8"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120661"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000206"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23870"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41390"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213030"},{"issue":"5","key":"e_1_2_8_11_1","first-page":"493","article-title":"Serum interleukin\u20106 levels and joint involvement in polyarticular and pauciarticular juvenile chronic arthritis","volume":"10","author":"De Benedetti F","year":"1992","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"e_1_2_8_12_1","first-page":"253","article-title":"Relation of interleukin\u20106, TNF\u2010alpha and interleukin\u20101alpha with disease activity and severity in juvenile idiopathic arthritis patients","volume":"58","author":"Sp\u00eerchez M","year":"2012","journal-title":"Clin Lab"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32832f1445"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380209"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.061853"},{"key":"e_1_2_8_16_1","unstructured":"Kevzara.Prescribing information. Accessed May 15 2025. Sanofi;2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761037s015lbl.pdf"},{"key":"e_1_2_8_17_1","unstructured":"European Medicines Agency.Kevzara summary of product characteristics. Accessed May 15 2025.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/kevzara\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205351"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4071-9"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02303-y"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41528"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0361-4"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-026-10024-z"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204405"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39944"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39093"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1795"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38092"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205372"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead490"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30025-4"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25339"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30367"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210310"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100986"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key361"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180795"},{"key":"e_1_2_8_38_1","unstructured":"European Medicines Agency.RoActemra (tocilizumab) assessment report. Published September 7 2023. Accessed May 15 2025.https:\/\/www.ema.europa.eu\/en\/documents\/withdrawal\u2010report\/withdrawal\u2010assessment\u2010report\u2010roactemra_en.pdf"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-7-200704030-00004"},{"issue":"4","key":"e_1_2_8_40_1","first-page":"541","article-title":"Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials","volume":"56","author":"Moots RJ","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead062"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.25692","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr.25692","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.25692","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T09:23:21Z","timestamp":1779701001000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.25692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/acr.25692"],"URL":"https:\/\/doi.org\/10.1002\/acr.25692","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"2025-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}